Aster Insights’ Post

The news is out! 🌟 We're thrilled to announce that we've been selected to present in an oral Minisymposium during the upcoming #AACR24 Annual Meeting. Our presentation will showcase two of our predictive PROphet® tools, which can be used independently or in combination for advanced #NSCLC patients: 1️⃣ One to guide treatment decisions by assessing a patient's probability of benefiting from immune-checkpoint inhibitor (ICI) therapy. 2️⃣ Another to assess the likelihood of patients experiencing severe immune-related adverse events (irAEs). "These findings are a source of great excitement for us, with our main commitment to bringing these advancements to healthcare providers and patients, improving cancer care globally." - Ofer Sharon, MD, CEO of OncoHost Read the full news release here: https://prn.to/4c3ZSZG Attending #AACR and want to meet? Schedule here: https://bit.ly/49VX5zF #Proteomics #CancerResearch #Biomarkers #BiomarkerDevelopment #PrecisionOncology #LCSM

We take raw data and turn it into valuable information that leads to meaningful insights in the fight against cancer. Clinicians, patients, data scientists, and biologists collaborate to improve cancer care. Its a beautiful thing. Were honored to have been chosen for an oral presentation at the upcoming @AACR conference. Excited to share our research with the scientific community! #AACR #research #science #OncoHost #CancerResearch #MakingADifference #nomatterwhat

As we observe Cervical Cancer Awareness Month this January, let's take a moment to appreciate the remarkable strides in cancer drug innovation. The integration of bench science and data science has paved the way for groundbreaking solutions, particularly in precision therapeutics, showcasing the transformative potential for patients facing devastating diseases like cervical cancer. Have you witnessed innovation shape the landscape of cancer drug development? Share your insights on the latest breakthroughs and the impact they can have. Let's engage in a conversation that amplifies awareness and understanding during this crucial month. #CervicalCancerAwareness #InnovationInCancerDrugs #HealthcareAdvancements #PrecisionTherapeutics #MedicalInnovation #qualityinnovation #drugapproval

Anal Cancer Market size was valued at USD 698 Mn. in 2023 and the total Anal Cancer Market size is expected to grow at a CAGR of 6.4% from 2024 to 2030, reaching nearly USD 1077 Mn. by 2030. The anal cancer market is witnessing significant growth due to increased awareness, advancements in treatment options, and rising incidences globally. Innovations in early detection and personalized therapies are paving the way for improved patient outcomes. As the healthcare industry continues to prioritize research and development, we can expect more breakthroughs that enhance the quality of life for those affected. Request for sample report:https://lnkd.in/dwTXCjRD #AnalCancerAwareness #HealthcareInnovation #CancerResearch

Cancer vaccine development has experienced few successes, but hope is on the horizon with novel neoantigen-based therapies. Download this Oracle Life Sciences PDF to learn why: https://lnkd.in/e6abTTtd

Cancer vaccine development has experienced few successes, but hope is on the horizon with novel neoantigen-based therapies. Download this Oracle Life Sciences PDF to learn why: https://lnkd.in/eWTSj34M

Cancer vaccine development has experienced few successes, but hope is on the horizon with novel neoantigen-based therapies. Download this Oracle Life Sciences PDF to learn why: https://lnkd.in/gGPzbK5m

Advances in multiple myeloma (MM) treatment include effective minimal residual disease (MRD) testing. The clonoSEQ assay, the only FDA-cleared MRD test for MM, uses next-generation sequencing (NGS) to monitor treatment success. NCODA’s PQI on clonoSEQ® Next Generation Sequencing for Minimal Residual Disease Testing in Multiple Myeloma PQI highlights MRD testing’s crucial role, especially during maintenance phases, ensuring effective and less intensive therapy. Collaborating with NCODA, Florida Cancer Specialists & Research Institute and Rocky Mountain Cancer Centers share their insights on utilizing this PQI to streamline best practices and enhance care for MM patients.  Read more: https://bit.ly/4ghzIEC

Today is #WorldLungDay, an observance that encourages communities & governments to invest in #lunghealth. Lung cancer is the #1 cause of cancer death worldwide and #DELFI's high-performing blood-based #FirstLook Lung test is designed to increase participation in screening. Our collaborations with OSF HealthCare, Indigenous Pact PBC, Inc., City of Hope, and our CASCADE-LUNG and other research partners highlight our commitment to ensuring that new genomic technologies can reach more eligible individuals and make a lasting impact on early cancer detection. Learn more about our FirstLook Test here: https://lnkd.in/e8A99QzF #LungCancer #CancerScreening #EarlyDetection #GenomicTechnology

According to recent research, cancer cases are on course to top 35 million globally by 2050, making the need for better prevention methods, faster diagnostic tools and innovative treatments greater than ever. However, it's important to not forget how far we have come and in the last 5 decades, survival rates for cancer have doubled. This significant progress is a testament to the collective efforts of the medical community, researchers, and advancements in technology and treatment methods. At Proclinical, we are proud to support the work of our partners who are committed to unraveling the complexities of cancer and providing ground-breaking ways to live with and treat the disease. #GlobalGrowthPartners #WorldCancerDay #Cancer #Oncology #MedicalAdvancement #LifeSciences #MedicalTechnology #Pharma